CALGARY, Alberta, June 10, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading, international scientific conferences including: the American Diabetes Association’s (ADA) 79th Scientific Sessions 2019, the 56th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress 2019, the 2019 FSHD International Research Congress and the Alzheimer’s Association International Conference (AAIC) 2019, details of which are listed below.
In addition, through an unrestricted grant, the Company is supporting an educational symposium during ERA-EDTA titled: “Vascular calcification in kidney disease: Epigenetics as a novel approach?” where key opinion leaders will review the role of epigenetics and BET-inhibition as a novel strategy to improve outcomes in cardiovascular and chronic kidney disease patients. Further details on the educational symposium, including presentation materials, are available below.
Of note, members of the Company’s Clinical Steering and Advisory Boards will be presenting information on BET inhibitor, apabetalone, at key conferences. During ERA-EDTA, Dr. Kamyar Kalantar-Zadeh, MD – UC Irvine School of Medicine, Irvine, CA, will present a poster titled: Apabetalone, a Selective Bromodomain and Extra-Terminal (BET) Inhibitor, Reduces Serum FGF23 in Cardiovascular Disease and Chronic Kidney Disease Patients. During AAIC, Dr. Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center, Las Vegas, NV, will present a poster titled: Effects of the Epigenetic BET-Inhibitor Small Molecule Apabetalone on Cognition in Patients with Diabetes and Cardiovascular Disease.
Dr. Ewelina Kulikowski, Senior Vice President, Research & Development for the Company will deliver an oral presentation during ERA-EDTA titled: Apabetalone, an Inhibitor of BET Proteins, Improves Cardiovascular Risk and Reduces Alkaline Phosphatase in both CVD Patients and Primary Human Cell Culture Systems and Dr. Christopher Sarsons, Applied Research Scientist, Resverlogix, will deliver the oral presentation: Apabetalone, a CVD Phase 3 Clinical-stage BET Inhibitor, Opposes DUX4 Expression in Primary Human FSHD Muscle Cells, during the FSHD International Research Congress.
Through participation at leading industry events, the Company continues to highlight apabetalone and its ability to regulate multiple biological pathways that underlie, and are known to contribute to, cardiovascular, diabetes, kidney, neurodegenerative and certain orphan diseases. On April 18, 2019, the Company announced that BETonMACE has successfully reached its targeted 250 projected major adverse cardiac events (MACE) moving the trial towards completion.
Details on Upcoming Presentations:
Note: Applicable posters will be available on the Company’s website HERE at the appropriate time.
ADA Scientific Sessions, San Francisco, USA
- June 10th, 2019
- Poster Presentation: Apabetalone (RVX-208) Attenuates an Inflammatory Milieu that Enhances Adhesion of Monocytes to Endothelial Cells in Type 2 Diabetes Mellitus with Cardiovascular Disease Patients
ERA-EDTA Congress, Budapest, Hungary
- June 14, 2019
- Poster Presentation: Apabetalone, a Selective Bromodomain and Extra-Terminal (BET) Inhibitor, Reduces Serum FGF23 in Cardiovascular Disease and Chronic Kidney Disease Patients
- June 14, 2019
- Oral Presentation by Dr. Ewelina Kulikowski, Senior Vice President, Research & Development, Resverlogix: Apabetalone, an Inhibitor of BET Proteins, Improves Cardiovascular Risk and Reduces Alkaline Phosphatase in both CVD Patients and Primary Human Cell Culture Systems
- June 15, 2019
- Through an unrestricted educational grant, the Company is supporting a symposium titled: Vascular calcification in kidney disease: Epigenetics as a novel approach?
- The symposium will review the role of epigenetics and BET-inhibition as a novel strategy to improve outcomes in cardiovascular and chronic kidney disease patients
- The symposium presentations will be made available on the Company’s website HERE shortly after the live event (~1 ½ hours) which is scheduled for 13:15 local time.
FSHD International Research Congress, Marseille, France
- June 20, 2019
- Oral Presentation by Dr. Christopher Sarsons, Applied Research Scientist, Resverlogix: Apabetalone, a CVD Phase 3 Clinical-stage BET Inhibitor, Opposes DUX4 Expression in Primary Human FSHD Muscle Cells
AAIC, Los Angeles, USA
- July 14, 2019
- Poster Presentation: Effects of the Epigenetic BET-Inhibitor Small Molecule Apabetalone on Cognition in Patients with Diabetes and Cardiovascular Disease
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone in the treatment of patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
